Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics sold by majority-owned joint venture ViiV Healthcare, which helped group ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

including Blenrep for multiple myeloma and depemokimab for severe asthma. CEO Emma Walmsley emphasized prioritizing R&D in respiratory, oncology, and HIV treatments. For 2025, GSK expects turnover ...

plus over 4 billion pound sterling in combined peak sales from Nucala and the near-market long-acting IL-5 drug depemokimab, will help boost the contribution of GSK's specialty medicines portfolio ...

Strong full-year trading and an improving outlook have propelled GSK’s share price higher, as Royston Wild explains. The content of this article is provided for information purposes only and is ...

GSK said it now e American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast.